18:45 ACTU Actuate announced that its Board of Directors authorized the increase of its existing stock repurchase program by over 50% for the first quarter of fiscal year 2008.
……
18:43 RMIX U.S. Concrete announces divestiture of its Memphis, Tennessee operations (4.30 +0.2
Co announced that it has sold its Memphis, Tennessee operations to Memphis Ready Mix. The sales price was ~$7.2 mln, plus payment for certain inventory on hand at closing. During 2006 and 2007, these operations generated revenues of $24.4 mln and $14.5 mln on ready-mixed concrete volumes of 302,000 and 179,000, respectively. During 2006 and 2007, the Memphis operations generated pre-tax losses of $1.3 mln and $2.8 mln, respectively. For 2007 financial reporting purposes, the financial results of these operations will be reflected under the caption, “Results of Discontinued Operations” and the Co will also reflect a loss on the sale of these assets. The sales proceeds will be invested and available for general corporate purposes. Co says, “The sale of our Memphis operations represents another step in our strategy of exiting markets that do not meet our performance and return criteria nor fit our strategic objectives. Based on its historical performance and our outlook for 2008, this transaction will be accretive to our 2008 earnings EPS, operating margins and cash flow.”
18:34 SVNT Savient Pharma reports additional positive trial data for secondary endpoints from Puricase (pegloticase) Phase 3 studies (19.95 -0.0
Co announced additional positive results for secondary efficacy endpoints in the two replicate Phase 3 studies for Puricase (pegloticase) for treatment-failure gout. Results were favorable for the treatment effect on clinical outcomes assessed by the reduction in the number of tender and swollen joints, and in improvement in Patient Reported Outcomes (PRO) as measured by Short Form-36 (SF-36) and the Health Assessment Questionnaire - Disability Index (HAQ-DI). These endpoints were assessed in a pre-specified pooled analysis from the two replicate studies and are reported for the Intent-to-Treat population. The improvement reported in these outcomes was clinically meaningful as determined by the pre-specified definitions. The co previously reported that pegloticase had met the pre-specified primary efficacy endpoint, i.e. normalization of plasma uric acid for every two week and every four week dose administration, independently, in each of the two Phase 3 studies.
18:27 WGL WGL Holdings misses by $0.06, beats on revs; raises FY08 EPS above consensus (32.80 +0.47)
Reports Q1 (Dec) earnings of $0.96 per share, excluding non-recurring items, $0.06 worse than the First Call consensus of $1.02; revenues rose 2.5% year/year to $751.6 mln vs the $652 mln consensus. Co raises guidance for FY08, sees EPS of $2.35-2.45, excluding non-recurring items, vs. $2.29 consensus.
18:23 APC Anadarko Petro beats by $0.01, beats on revs (59.75 -0.29)
Reports Q4 (Dec) earnings of $0.78 per share, excluding non-recurring items, $0.01 better than the First Call consensus of $0.77; revenues fell 3.8% year/year to $3.06 bln vs the $2.67 bln consensus. Co Anadarko estimates its worldwide proved reserves at year-end 2007 totaled 2.43 billion BOE. In 2007, excluding the effect of divestitannounced the details of its 2008 capital budget and provided production estimates for 2008. Anadarko’s Board of Directors has approved total capital expenditures, including expensed exploration, of $4.5 to $4.7 billion. The capital program includes approximately 20% for exploration activities. ures, the company added approximately 250 million BOE of proved reserves and incurred costs in exploration and development activities of approximately $3.84 billion. Co
18:19 BDX Becton Dickinson meets FDA warning letter commitments for a plant - DJ (88.20 +1.03)
18:04 TDC Teradata reports FY07 record revs (24.27 +0.66)
Co reported 18.7% revs growth to $2.15 bln revs for FY07 vs $1.7 bln dual-analyst est. Co says, “Business iIntelligence applications drive 15% frowth in sales… we are not seeing a downward trend.”
17:59 SHW Sherwin-Williams: Farallon Capital Management reports a 5.2% stake in the co in an SC 13D (56.16 -2.05)
17:55 MKTIN Market Internals -Update-
The Dow was down 0.85% at 12635, the Nasdaq was down 1.26% to close at 2383, and the S&P was down 1.05% to close at 1381. Leading sectors included: Trucking +3.2%, Health Care Facilities +3.1%, Independent Power Producers and Energy Traders +2.1%, Wireless Services +1.8%, Oil and Gas Drillers +1.7%. Lagging sectors included: Diversified Banks -6.3%, Homebuilding -6.0%, General Merchandise Stores -5.6%, Consumer Finance -5.5%, Home Furnishings -5.1%. Today’s movement came from lower than avg volume (NYSE 1360, vs. 1613 avg, Nasdaq 2075, vs. 2270 avg), with decliners outpacing advancers (NYSE advance/decline 1360/1983, Nasdaq 1254/168
with new lows outpacing new highs (NYSE new high/new low 46/54; Nasdaq 54/70).
17:54 SPRD Spreadtrum Comms reports Q4 earnings above consensus; issues in line Q1 rev guidance (10.34 +0.97)
Co reports Q4 GAAP earnings per ADS of $0.22 vs $0.17 First Call consensus; revs rose 57% YoY to $48.5 mln vs $46.63 mln First Call consensus. Co sees Q1 revs $39-40 mln vs $39.87 mln First Call consensus. The co estimates its operating margin in 1Q08 should be in the range of 4%-5%. Excluding Quorum, the Company’s operating margin should be approximately 9%- 10%.
17:51 LVS Las Vegas Sands: Earnings conf call summary (81.45 -6.40) -Update-
The co did not provide guidance, as is its custom… Says the Venetian’s hold was about two points below what the co expected, but as the property opens, expects to see normal hold levels. Co admits it is working on the margins as it figures out the various business segments and the exact staffing levels needed to efficiently operate that property. Specifically, missed some opportunities to maximize revenue by selling tickets at a higher price for certain events… The ferry is up and operating — offering service every half hour. Co is waiting for the approval of additional slips in Hong Kong, which will allow 24-hour sailing for the night crews. As the co adds more ferries and get into full operations, service should ramp up to every 15 minutes… Co has offered junket reps to the Venetian Macao new commission rates, which began on Feb 1. The hold rate now affects the commission — reps share a portion of the downside if the expected hold percentage is not reached, which is the current state, though they get more upside if the hold percentage is met. Says competitors already use this type of structure… Co says there are no more waves of competition on the peninsula; no developments in the foreseeable future (this has affected the Sands Macao’s mass-market revenues in 2H07). Notes during expansion, Macao market has increased nearly 4x over a 5-yr period… Co has a tax holiday in Macao through 2008, when it expires. But fully expects it to continue based on a tax holiday given to Stanley Ho on the peninsula… Stock trading ~$83 after hours (hit a low of $74.95 following the release before quickly bouncing).
17:46 FEIC FEI Company Earnings Color (22.10 -1.09) -Update-
Co reported Q4 (Dec) earnings of $0.25, excluding a $0.15 tax benefit, which appears to be comparable to the $0.26 First Call consensus.
17:41 ALXN Alexion Pharm announced in an 8-K that SB2, Inc. filed a civil action against the co (68.32 -0.52)
Co announced in an 8-K that on January 31, 2008, SB2, Inc. filed a civil action against ALXN in the U.S. District Court for the Northern District of California. SB2, Inc. claims willful infringement by Alexion of SB2, Inc. patents. SB2, Inc. seeks, among other things, monetary damages and equitable relief.
17:39 UTR Unitrin misses by $0.30, misses on revs (42.10 +0.13)
Reports Q4 (Dec) earnings of $0.29 per share, including $0.21 from discontinued operations, $0.30 worse than the First Call consensus of $0.59; revenues rose 2.0% year/year to $723.3 bln vs the $754.6 mln consensus.
17:34 SIRF SiRF Technology Earnings Call Summary (16.27 +0.22)
On call the co guides Q1 EPS to ($0.04)-$0.00 vs $0.24 First Call consensus; sees revs $71-77 mln vs $92.37 mln First Call consensus. “In reviewing our revenue forecast for Q1 and comparing with Q4, we are seeing typical seasonal declines in ordering from our traditional customer base. This year, however, our seasonal decline will be accentuated due to the decision of the S.O.C business through our Centralty acquisition. This business is currently driven by mostly tier 2 and white box customers in China, who typically present a much larger revenue decline from Q4 to Q1, because their annual volume is highly concentrated on the holiday season. In addition, we do not expect demand from our wireless customers to offset these declines in Q1″… The co says “gross margin performance was negatively impacted by a combination of competitive market pricing and a shift of product mix. This product-mix shift was triggered by late-breaking demand softness from two major customers, and a general weakness in the Korean market. This resulted in gross margin and ultimately EPS lower than we had anticipated. Going forward, we now expect to see our gross margin at approximately 50% for the near future, driven primarily by increasing competitiveness in the PND market segment and by our anticipated product mix. Our market share in Q4 was negatively impacted at one major customer, partially offset by share gains elsewhere”… The co says it expects the wireless market to provide good growth opportunities. “The customers, which have lost GPS-enabled product, they’re doing quite well, and wireless has been showing good growth for us in the last two quarters, and we expect it to become an increasing part of our mix this year”… The co sees the GPS option in the hand-set increasing. “Going forward, there are going to be multiple ways of wiring GPS into the hand-sets. We believe there will be a substantial portion which will be stand-alone, but also an increasing mix that would be what we call multifunction radios, whether that’s GPS with Bluetooth, GPS with wi-fi, GPS with wiMax, there are multiple combinations possible, and there are some of those combinations which we will be involved with, and what I don’t think there’s going to be one fixed way of integration of GPS into the hand-sets. If you look at some of our competitors are integrating into the base band. Some of us who stand alone are integrated into the multifunction radios or integrated into the application processes. So if you look at all of those four matters, SIRF is capable of doing at least three of them today.”
17:34 MTW Manitowoc beats by $0.06, beats on revs; guides FY08 EPS in-line (39.13 -0.04)
Reports Q4 (Dec) earnings of $0.74 per share, excluding non-recurring items, $0.06 better than the First Call consensus of $0.68; revenues rose 44.2% year/year to $1.12 bln vs the $1.01 bln consensus. Co reaffirms in-line guidance for FY08, sees EPS of $3.20-3.40, excluding non-recurring items, vs. $3.33 consensus. Co is also increasing their 2008 capex guidance to ~$120 mln.
17:32 UTR prelim $0.29 vs $0.59 First Call consensus; revs $723.3 mln vs $754.60 mln First Call consensus
17:31 BOOT LaCrosse Footwear announces $1.00 special dividend (14.51 )
17:31 PPS Post Properties beats by $0.04, reports revs in-line; Board authorization to seek a potential sale of the company (43.28 +0.66)
Reports Q4 (Dec) funds from operations of $0.51 per share, includes $0.03 gain on land sale and including $0.1 mln charge, $0.04 better than the First Call consensus of $0.47; revenues rose 4.8% year/year to $78.1 mln vs the $78.2 mln consensus. On January 23, 2008, the Co announced that its Board of Directors had authorized management, working with financial and legal advisors, to initiate a formal process to pursue a potential sale or other business combination and to seek proposals from potentially interested parties. The process commenced immediately after the announcement and is continuing. As a result of the commencement of the process discussed above, the Co will not provide earnings or FFO guidance for 2008.
17:31 CTS CTS awarded production program for smart actuators worth approx $75 million (10.62 )
The co announces that CTS Automotive Products was awarded a new production program for a smart actuator by a global diesel engine manufacturer. The smart actuator is used as a key part of a turbocharger system. This initial application will be used on diesel engines for light duty diesel trucks sold in the North American market with production beginning late 2009. Total revenues over the life of this six-year program are expected to be approximately $75 million.
17:29 SEPR Sepracor Q4 Earnings Preview (29.08 -0.29) -Update-
SEPR is expected to report Q4 earnings 2/5 before the mkt opens, the conference call has been temporarily delayed to ~2/29 (since co is in process of determining past restatements co may report only revs)… SEPR Consensus: First Call consensus is Q4 EPS of $0.54 on revs of $343.43 mln; Q1 EPS of $0.58 on revs of $325.94 mln; FY07 EPS of $1.46 on revs of $1.24 bln; FY08 EPS of $2.32 on revs of $1.34 bln… Guidance: Co reaffirmed guidance at JPMorgan Healthcare conference on 1/9, co sees FY07 EPS of $1.33-1.43 (excluding $0.28 charge and including restructuring costs, may not be comparable to $1.46 First Call consensus) on revs $1.23-1.30 bln vs $1.24 bln First Call consensus. Co also sees FY08 EPS of $2.35-2.45 vs $2.32 First Call consensus… Expectations: Since 2000, co has beaten earnings estimates 26 times (missed only 4 times) and beat Q4 estimates for past 4 years by at least $0.21. Revs growth YoY for Q4 has been >14.8% for past 8 years, but growth has slowed over the past year (revs growth actually declined last qtr -1.9%). For the most part, slower Rx trends have dampened Q4 and 2008 expectations, but estimates still remain plausible with new deals in the pipeline (such as Ciclesonide franchise deal with Nycomed and Bial collaboration)… As for particular drug numbers, Q4 estimates (based on single analyst estimates) are Lunesta $160 mln ($612 mln for the year), Xopenex/XopenexHFA $185 mln ($587 for the year) and Brovana $12 mln. In July, co stated on call it expects FY07 Lunesta sales of $595-615 mln and Xopenex sales of $495-515 mln… Areas of Focus: 1) Drug numbers 2) FY08 outlook (co usually gives more detailed guidance on call which has been delayed until the end of the month) 3) update on recently announced Nycomed agreement 4) update on recently announced (1/2
internal review of government price reporting (co also disclosed statements for periods back to 2002 should no longer be relied upon) 5) competition such as market risk for Lunesta as Ambian goes generic and NBIX’s Indiplon 6) takeover speculation that JNJ may place bid… Recent price movement: Since reporting last qtr, stock is trading up 8%. Stock is up 2% over past 20 days, up 1% over past week. The stock has made some notable moves after releasing earnings/guidance in the past. Last qtr the co gapped up ~14% after reporting (beat by $0.11 and issued mixed guidance) and on 7/27 the stock traded down ~25% after co missed estimates by $0.31 and revised guidance on conference call (in significant part due to the CMS changes on Xopenex inhalation solutions)… Based on its options volatility, implied volatility is up 72% vs its historical volatility (over 30 day period) and its implied 1-day % change move is ~4%… Briefing note: Short interest is 9%, mkt cap is $3.24 bln, float is 110.48 mln and avg volume is 2.2 mln. Due to the high short interest and relatively modest float, any upside guidance could fuel a move higher… Secondary plays: GSK, SNY, CRTX, PRX, MYL, WPI… Technical Levels of Interest: Please see chart for the Levels of Interest (Note that the length of horizontal line correlates with strength of support or resistance level). (PVIEW)
17:29 MTW prelim $0.74 vs $0.68 First Call consensus; revs $1.12 bln vs $1.01 bln First Call consensus
17:27 OMI Owens & Minor beats by $0.03, reports revs in-line; guides FY08 EPS in-line, guides FY08 revs in-line (41.39 +0.01)
Reports Q4 (Dec) earnings of $0.55 per share, $0.03 better than the First Call consensus of $0.52; revenues rose 6.0% year/year to $1.75 bln vs the $1.74 bln consensus. Co issues in-line guidance for FY08, sees EPS of $2.20-$2.30 vs. $2.25 consensus. Co guides FY08 rev growth to 5-7%, which equates to $7.14-$7.28 bln, in-line with consensus of $7.18 bln.
17:26 NVDA NVIDIA to acquire AGEIA Technologies, terms not disclosed (25.88 -0.84)
Co announces that it has signed a definitive agreement to acquire AGEIA Technologies. AGEIA’s PhysX software is widely adopted with more than 140 PhysX-based games shipping or in development on Sony Playstation 3, Microsoft XBOX 360, Nintendo Wii and Gaming PCs.
17:25 TMA Thornburg Mortg beats by $0.06, reinstates 4Q common stock dividend of $0.25 per share (11.28 -0.37)
Reports Q4 (Dec) earnings of $0.33 per share, $0.06 better than the First Call consensus of $0.27. Co reinstates 4Q common stock dividend of $0.25 per share. “Declaration and payment of 4Q common stock dividend of $0.25 per share underscores co’s optimism for continued profitable growth in 2008 and commitment to rebuilding shareholder value. 4Q mortgage originations of $516.7 mln signals a return to growth on the strength of our lending partner relationships…. Our return to profitability in the fourth quarter during a period of continued unprecedented industry turmoil is testament to the strength of our business model and our conservative approach to risk management, as well as further validation of our focus on quality across all aspects of our business… Our decisive actions to opportunistically raise capital and adapt our hedging and financing strategies in the face of difficult market conditions enabled us to manage successfully through the market’s turmoil in the fourth quarter, and we are confident that these same strategies along with new asset acquisition opportunities will help us continue to provide earnings and dividend growth for shareholders in the future while gaining market share in the prime jumbo mortgage origination business… From a company perspective, there are a lot of positive trends that began to materialize in the fourth quarter including: our declaration and subsequent payment of the common dividend, the fact that our fourth quarter earnings were clearly above the current dividend level and above the consensus estimates, a decline in our cost of funds versus the third quarter and our ability to successfully finance our mortgage loans through securitization at an attractive cost of funds and spread. In addition to these highlights of our fourth quarter, the mortgage market’s continued turbulence has provided ample new mortgage investment opportunities with improved spread opportunities, and our origination business continues to experience dramatic growth since the end of the third quarter. Finally, our portfolio duration has increased to the upper end of our allowable policy range of one year suggesting that we expect our portfolio margins and spreads to continue to improve in the near term.”
17:23 PPS prelim funds from operations of $0.51 vs $0.47 First Call consensus; revs $78.1 mln vs $78.15 mln First Call consensus
17:21 OMI sees FY08 $2.20-2.30 vs $2.25 First Call consensus; sees revs growth of 5-7%
17:20 OMI prelim $0.55 vs $0.52 First Call consensus; revs $1.75 bln vs $1.74 bln First Call consensus
17:16 TMA Thornburg Mortg reinstates 4Q common stock dividend of $0.25 per share (11.28 -0.37) -Update-
17:16 TMA prelim $0.33 vs $0.27 First Call consensus
17:13 EFX Equifax beats by $0.02, reports revs in-line; guides Q1 EPS in-line, revs below consensus; guides FY08 (36.57 -0.43)
Reports Q4 (Dec) earnings of $0.59 per share, excluding non-recurring items, $0.02 better than the First Call consensus of $0.57; revenues rose 25.9% year/year to $490.9 mln vs the $487.2 mln consensus. Co issues guidance for Q1, sees EPS of $0.56-0.61 vs. $0.61 consensus; sees Q1 revs of $488-498 mln vs. $512.67 mln consensus. Co issues guidance for FY08, sees EPS of $2.48-2.58 vs. $2.54 consensus; sees FY08 revs up 9-12%, or roughly $2.0-2.06 bln vs. $2.09 bln consensus.
17:11 ALAB Alabama Natl Banc, RY and RBC Centura Banks announce extension of deadline in connection with pending merger (78.14 -0.31)
ALAB, Royal Bank of Canada (RY) and RBC Centura Banks announce that the deadline for ALAB stockholders to make an election to receive cash or RBC common shares (or a combination of cash and shares), subject to proration, in connection with the pending merger between RBC Centura and ANB, has been extended from 6 pm ET on 2/8 to 6pm ET on 2/14, unless further extended. Cos continue to expect to complete the merger during RBC’s second fiscal quarter.
17:10 SOHU Sohu.com beats by $0.08, beats on revs; guides Q1 EPS above consensus, revs above consensus (48.95 -1.54)
Reports Q4 (Dec) earnings of $0.39 per share, including stock based comp, $0.08 better than the First Call consensus of $0.31; revenues rose 90.1% year/year to $65.3 mln vs the $55.4 mln consensus. Co issues upside guidance for Q1, sees EPS of $0.34-$0.37, including stock based comp, vs. $0.32 consensus; sees Q1 revs of $66.5-$68.5 mln vs. $59.00 mln consensus. Co states, “…With the Beijing 2008 Olympic Games kicking off in 185 days, the Sohu brand resonates across China as we broaden our media reach to penetrate the Olympic audience. We expect the continued expansion of the total Chinese internet population, combined with our advancements in technology and our Olympic sponsorship, to help us to increase our market share of internet users. We believe that we will continue to reap the rewards of our success and strong branding for 2008 and beyond.”
17:10 PWAV Powerwave misses by $0.05, beats on revs (3.81 -0.11)
Reports Q4 (Dec) loss of $0.07 per share, excluding non-recurring items, $0.05 worse than the First Call consensus of ($0.02); revenues rose 35.8% year/year to $230.6 mln vs the $227.1 mln consensus.
17:09 BSX Boston Scientific beats by $0.15, beats on revs; guides Q1 EPS above consensus, revs in-line (12.85 +0.4
Reports Q4 (Dec) earnings of $0.24 per share, excluding charges and amortization expense, $0.15 better than the First Call consensus of $0.09; revenues rose 4.2% year/year to $2.15 bln vs the $2.13 bln consensus. Co issues mixed guidance for Q1, sees EPS of 0.15-0.20, excluding charges and amortization expense, vs. $0.12 consensus; sees Q1 revs of 1.96-2.08 bln vs. $2.09 bln consensus. Co also reported Worldwide sales of the co’s drug-eluting coronary stent systems were $435 mln, as compared to $506 mln. U.S. sales of drug-eluting coronary stent systems were $224 mln, as compared to $329 mln. International sales of drug-eluting coronary stent systems were $211 mln, as compared to $177 mln. Worldwide sales of coronary stent systems were $496 mln, as compared to $550 mln. U.S. sales of coronary stent systems were $250 mln, as compared to $347 mln. International sales of coronary stent systems were $246 mln, as compared to $203 mln. Co also said Full-year 2008 sales and earnings per share guidance will be provided during the co’s conference call with analysts tomorrow.
17:09 SXI Standex Int’l reports Q4 EPS of $0.45 vs $0.38 a year ago; revs rose 23.6% to $172.2 mln (18.40 )
17:09 PRE PartnerRe beats by $1.36, beats on revs (79.90 +0.42)
Reports Q4 (Dec) earnings of $4.55 per share, excluding non-recurring items, $1.36 better than the First Call consensus of $3.19; revenues fell 4.7% year/year to $1.1 bln vs the $906.7 mln consensus.
17:07 ARRY Array Biopharma beats by $0.04, beats on revs (6.58 +0.05)
Reports Q2 (Dec) loss of $0.43 per share, $0.04 better than the First Call consensus of $(0.47); revenues rose 11.3% year/year to $8.4 mln vs the $7.3 mln consensus. This month, ARRY anticipates completing a Phase 2 acute inflammatory pain study with ARRY-797, a pan-cytokine inhibitor. Given appropriate results, ARRY plans to aggressively advance this drug in both pain and inflammatory disease indications.
17:06 YUM YUM! Brands beats by $0.02, beats on revs; guides FY08 EPS below consensus (35.81 +0.57)
Reports Q4 (Dec) earnings of $0.44 per share, $0.02 better than the First Call consensus of $0.42; revenues rose 8.2% year/year to $3.26 bln vs the $3.14 bln consensus. Co issues downside guidance for FY08, sees EPS of $1.79, excluding $0.06 in gains, vs. $1.87 consensus, vs prior $1.82-1.85. Co says, “We are confident we can continue to build on our track record of growing EPS at least 10% each year by generating 20% operating profit growth from our China Division, 10% from our YRI Division and 5% from our U.S. businesses… In Q1 of 2008, we expect the following one-time impacts: pre-tax gain of ~$87 mln from the sale of our minority interest in KFC Japan; charges of up to $10 mln before taxes related to G&A productivity initiatives and realignment of resources to drive stronger U.S. brand growth; and expected refranchising losses of about $20 mln.
17:05 NTCT NetScout Systems reports Q3 (Dec) results, beats on revs; guides Q4, Y09 (9.54 -0.11)
Reports Q3 (Dec) GAAP loss of $0.09 per share, non-GAAP EPS of $0.17, may not be comparable to the First Call consensus of ($0.21); GAAP revenues rose 102.6% year/year to $53.7 mln, non-GAAP revs of $60 mln, may not comapre to the $47.6 mln consensus. Co issues guidance for Q4, sees GAAP EPS of ($0.18)-($0.22), non-GAAP EPS of $0.04-0.08, may not be comparable to $0.07 consensus; sees Q4 GAAP revs of $54-58 mln, non-GAAP revs of $60-64 mln, vs. $55.11 mln consensus. Co issues guidance for FY09, sees GAAP EPS of $0.08-0.18, non-GAAP EPS of $0.50-0.60, may not be comparable to $0.46 consensus; sees FY09 GAAP revs of $250-260 mln, non-GAAP revs of $260-270 mln, vs. $240.41 mln consensus.
17:04 HHGP Hudson Highland Grp pre-announces Q4 results; announces $15 mln share buyback (7.15 -0.06)
Co will report Q4 2007 revenue of $290.5 million, First Call consensus is $333.3 mln, and adjusted EBITDA of $13.5 million from continuing operations. The co’s discontinued operations include the Netherlands Reintegration business it sold in December 2007 and the Energy and Engineering business it sold earlier today. For comparison purposes, including the results of discontinued operations in Q4 would have resulted in revenue of $331.5 million, compared with guidance of $325 - $340 million, and adjusted EBITDA of $14.3 million, compared with guidance of $12 - $14 million. The company also announced today that its board of directors has authorized the repurchase of up to $15 million of the company’s common stock. The company intends to make purchases from time to time as market conditions warrant.
17:04 EXXI Energy XXI beats by a penny, beats on revs (4.26 -0.03)
Reports Q4 (Dec) earnings of $0.07 per share, $0.01 better than the First Call consensus of $0.09; revenues rose 94% year/year to $153.7 mln vs the $149.41mln consensus. The fiscal-year 2008 capital budget, excluding acquisitions, is unchanged at approx $260 mln.
17:04 EFX sees Q1 $0.56-0.61 vs $0.61 First Call consensus; sees revs $488-498 mln vs $512.67 mln First Call consensus
17:04 YHOO Yahoo: NWS.A says not going to make a bid for YHOO - DJ (29.33 +0.95) -Update-
(NWS.A)
17:03 BSX sees Q1 $0.15-0.20 vs $0.12 First Call consensus; sees revs $1.96-2.08 bln vs $2.09 bln First Call consensus
17:03 EFX sees FY08 $2.48-2.58 vs $2.54 First Call consensus; sees annual revenue growth to be between 9%-12%
17:03 SOHU sees Q1 $0.34-0.37 including stock based comp, vs $0.32 First Call consensus; sees revs $66.5-68.5 mln vs $59.00 mln First Call consensus
17:03 YHOO Yahoo: Be careful with antitrust talk, lawyers tell Google - Globe and Mail (29.33 +0.95) -Update-
Globe and Mail reports GOOG’s effort to raise antitrust concerns about MSFT’s bid for Yahoo has several flaws, analysts said. For starters, regulators pay more attention to the views of customers and consumers than to those of competitors when reviewing consolidation, antitrust attorneys said. On its specific arguments against the acquisition, Google also may not have made the strongest case possible, these attorneys said. The biggest hurdle when one rival complains about another is that “the regulators suspect the deal might be good for competition,” Stephen Houck, a former antitrust enforcer in New York state, said Monday. “Google has to tread very carefully, lest it have a negative impact,” said Houck, who is counsel for a group of states, led by California, that pushed to extend court oversight of Microsoft’s landmark 2002 antitrust settlement.
17:02 WPP Wausau Paper reports Q4 EPS results (9.91 +0.2
Co reports Q4 EPS of ($0.03), excluding after-tax charge of $28.8 mln, or $0.58 per share, relating to the Dec 2007 closure of Printing & Writing’s paper mill in Groveton, NH; timberland sales gains of $2.0 mln, or $0.04 per share; stock incentive credits of $0.6 mln, or $0.01 per share; and one-time state tax benefits of $1.2 mln, or $0.02 per share, vs. ($0.04) First Call consensus; net sales increased 1% from a year ago to $304.5 mln… Commenting on the outlook for the first quarter of 2008, Mr. Howatt said, “Fiber prices continue to rise for all three businesses and signs of further economic weakness in the domestic economy add uncertainty to near-term demand. While execution of Printing & Writing’s profit recovery plan will provide modest benefit in the first quarter, its impact is expected to build over the balance of the year. Meanwhile, our Towel & Tissue unit continues to outperform the market, and corrective measures in response to product specific economic weakness at our Specialty Products business are underway. As a result, we expect near-breakeven results in the first quarter, excluding timberland sales gains, charges associated with the closure of the Groveton mill and the impact of stock incentives.”
17:02 YTEC Yucheng Technologies beats on EPS, revs (15.27 +0.23)
Co reports Q4 non-GAAP EPS of $0.26, excluding non-recurring items, vs $0.18 consensus; co reports revs up 89% yr/yr to $23.5 mln vs $16.2 mln consensus. Co sees Y08 revs of $71.5-74.5 mln vs $60.5 mln consensus; co sees non-GAAP net income of $14.7-15.2 mln.
17:02 BSX prelim $0.24 ex items vs $0.09 First Call consensus; revs $2.15 bln vs $2.13 bln First Call consensus
17:01 EFX prelim $0.59 vs $0.57 First Call consensus; revs $490.9 mln vs $487.20 mln First Call consensus
17:01 SOHU prelim GAAP $0.39 vs $0.31 First Call consensus; revs $65.3 mln vs $55.42 mln First Call consensus
17:00 IBAS iBasis reports Q4 EPS of ($0.03) vs $0.10 single analyst est; revs fell 4% YoY to $350.6 mln vs $378.90 mln single analyst est (5.53 -0.17)
Co also says it believes that in 2008 Adjusted EBITDA will be $60 to $70 mln and capital asset expenditures will be $30 to $35 mln. This guidance excludes the potential effects of the pending transaction with TDC, which has been announced but has not yet closed.
17:00 PGR Progressive: Moody’s withdraws Progressive’s shelf rating (18.53 -0.29)
Moody’s has withdrawn its provisional rating on the co’s $650 mln shelf registration (senior unsecured debt rated (P)A1) which was filed in October of 2002. Moody’s has withdrawn the rating as the shelf registration is no longer effective, having been withdrawn by the co.
17:00 ENTR Entropic Comms reports Q4 EPS of $0.05 vs $0.03 a month ago; revs rose 11% sequentially to $40.2 mln (6.42 )
16:59 VASC Vascular Solutions reports EPS in-line, beats on revs; guides Q1 EPS in-line, revs in-line; raises FY08 EPS in-line, reaffirmed revs in-line (6.00 -0.03)
Reports Q4 (Dec) earnings of $0.03 per share, in-line with the First Call consensus of $0.03; revenues rose 25.2% year/year to $14.4 mln vs the $13.7 mln consensus. Co issues in-line guidance for Q1, sees EPS of $0.04-0.06, excluding non-recurring items, vs. $0.05 consensus; sees Q1 revs of $14.5-14.8 mln vs. $14.58 mln consensus. Co raises EPS guidance, raises EPS in-line for FY08 to $0.25-0.33 vs. $0.25 consensus, up from $0.20-0.28; reaffirmed FY08 revs of $61-64 mln vs. $62.33 mln consensus.
16:59 SIRF SiRF Technology earnings color (16.27 +0.22) -Update-
It appears that the non-GAAP EPS of $0.28 is comparable to the First Call consensus of $0.32. See 16:32 comment for full report.
16:59 WOOF VCA Antech guides Q4 below consensus; guides FY08 EPS below consensus, revs in-line (39.50 -0.27)
Co issues downside guidance for Q4, sees EPS of $0.28-$0.29, which includes an after tax benefit of $0.03 related to a decrease in estimated workers compensation liabilty, vs consensus of $0.28; sees revs of $284 mln vs consensus of $290.46. For FY08, co issues downside EPS guidance, sees EPS of $1.55-$1.60 vs consensus of $1.63 and sees revs of $1.30 bln - $1.33 bln vs consensus of $1.32 bln. Co states, “Although it is apparent that the economy during the past several months has marginally impacted our growth rates, we remain optimistic of our long-term outlook and favorable trends in the animal healthcare industry…”
16:59 TZIX TriZetto Group beats by $0.02, guides Q1 EPS below consensus, guides FY08 in-line (18.87 -0.2
Reports Q4 (Dec) earnings of $0.16 per share, $0.02 better than the First Call consensus of $0.14; revenues rose 31.7% year/year to $116.5 mln vs the $115.4 mln consensus. For Q1, co sees EPS of $0.08-0.14 vs. $0.15 consensus; sees Q1 revs of $113-120 mln vs. $119.7 mln consensus. Co issues in-line guidance for FY08, sees EPS of $0.67-0.74 vs. $0.67 consensus; sees FY08 revs of $480-500 mln vs. $496.8 mln consensus.
16:59 CSC Computer Sciences reports preliminary Q3 results above consensus; guides Q4 and FY07 (42.09 -0.05)
Co reported preliminary Q3 EPS of $1.05, including charges of $0.06, vs. $1.00 First Call consensus; revs of $4.16 bln, up 14.3% from a year ago, vs. $4.06 bln First Call consensus. Sees Q4 EPS of $1.33-1.43, excluding items vs. $1.47 consensus; revs of $4.2-4.5 bln vs. $4.4 bln consensus. Sees full year EPS of $3.75-3.85, including the adoption of FIN 48, but excluding special items, vs. $3.80 consensus.
16:58 COF Capital One CEO Enters into Pre-Arranged Stock Trading Plan (52.65 -4.32)
Richard D. Fairbank, Chairman and Chief Executive Officer of Capital One Financial Corp (COF), today announced that he has adopted a pre-arranged stock trading plan to exercise approximately 1.13 million options to purchase Capital One stock. Mr. Fairbank will only sell shares issued upon exercise of the options sufficient to cover the exercise price of the options, taxes and other transaction-related expenses. Fairbank will retain the remainder of the shares. The plan covers stock options granted in April 1999 that will expire in April 2009.
16:58 BONDX Slumming Bonds
The market slumped into the end of the session with little to show for the day, heading out about mid-range in diminishing action with things dominated by tame spread trade. The market will be stuck in this lower, listless trade for the next few sessions as there is little between now & the upcoming auctions to get things revved up. The ISM report carries some water, but is unlikely to help much, more likely to hurt even if it shows worse than expected. The market will continue to work along a steeper slant on the curve trades as safe-haven buying has lost some urgency, yields remain near multi-yr lows while supply out the week is also weighing on the longer end prices. The 2-10-yr yield spread headed out at 157.7 with little but unwinding positions to knock things flatter. The dollar remains stuck in tight ranges against euro & yen. Currencies had little to work with today as data were near absent & Fed-speak didn’t even register. Spot gold pared losses to 902.38 (-3.10) while crude oil settled up at 90.02 (+1.19). Tomorrow hasISM services (10) & Richmond’s Lacker (12:15). The 10-yr is now -14/32 yielding 3.644%
16:57 OPNT OPNET announces a stock repurchase program of 1 million shares (9.24 -0.21) -Update-
16:56 RMKR Rainmaker Sys sees Q4 revs of $20 mln vs $19.52 mln consensus, announces termination of agreement with significant client (6.02 -0.24)
Co announces that it has been notified by a significant client of a change in corporate direction and intent to bring work in-house, resulting in a termination of its agreement with Rainmaker. The notification communicated on February 1, 2008 indicated the client intends to bring in approx half of the business internally today, and the remainder over a transition period of the next three months. Based on preliminary unaudited results, this client represented approx 25% of Rainmaker’s 2007 fourth quarter revenue, down from 28% in the preceding quarter and 35% in the year-ago quarter. The co has reduced this client’s revenue concentration as a result of many new client signings and client expansions over the last year. The co’s unaudited contract sales revenue in the fourth quarter, excluding this client, grew 33% sequentially from the prior quarter as new client programs are beginning to ramp. Based on preliminary, unaudited results, the co expects to report 2007 fourth quarter revenue of $20 mln vs $19.52 mln consensus, bringing total revenue for the full fiscal year to approx $73.5 mln, up 50% from 2006. The co expects to report GAAP profitability for the fourth quarter, representing its eighth consecutive GAAP profitable quarter. In the fourth quarter, Rainmaker generated approx $2.2 mln in operating cash flow and ended 2007 with $37 mln in cash and $2.4 mln in debt. The co also issues preliminary FY08 revenue guidance of $68 mln to $72 mln vs $91.6 mln consensus. Rainmaker will report fiscal 2007 fourth quarter and year end financial results on February 13, 2008.
16:56 NLY Annaly Mortgage reports EPS in-line (19.81 -0.1
Reports Q4 (Dec) earnings of $0.37 per share, in-line with the First Call consensus of $0.37. “While the extreme market turbulence that began in August 2007 has subsided, the US economy is in a tenuous position and fixed income market conditions remain volatile. Policymakers are taking aggressive steps to stimulate the economy and calm the markets through monetary and fiscal policy actions, and financial institutions are in the process of recapitalizing, but the success of these efforts is still evolving. In these conditions, while we continue to manage our portfolio conservatively, we are pleased that we are able to continue to demonstrate the accretive impact of sequential capital raises.”
16:54 OPNT OPNET misses by $0.03, misses on revs; guides Q4 EPS in-line, revs in-line (9.20 -0.25)
Reports Q3 (Dec) loss of $0.06 per share, $0.03 worse than the First Call consensus of ($0.03); revenues rose 6.1% year/year to $26 mln vs the $26.3 mln consensus. “While we anticipated the near term pressure our recent acquisition is putting on operating income, we believe the resulting acceleration in the expansion of our application performance management portfolio greatly enhances the Company’s growth opportunities. We are now in a stronger position to increase license revenue while managing expenses to grow operating income.” Co issues in-line guidance for Q4, sees EPS of -0.05-0.03 vs. ($0.01) consensus; sees Q4 revs of $26.5-28.5 mln vs. $27.39 mln consensus.
16:54 NETM NetManage reports Q4 EPS of $0.17 vs ($0.10) yr ago; revs rise 27% to $10.9 mln (50.7 -0.15)
16:54 AUTH AuthenTec beats by $0.01, guides Q1 revs above consensus (13.45 +0.43)
Reports Q4 (Dec) earnings of $0.04 per share, ex-items, $0.01 better than the First Call consensus of $0.03; revenues rose 66.8% year/year to $15.7 mln vs the $15.4 mln consensus. For Q1 (Mar), co sees EPS of $0.01-0.02 vs. $0.01 consensus; sees Q1 revs of $15.0-15.3 mln vs. $14.7 mln consensus. For FY08, co sees revs of $72-78 mln vs. $73.8 mln consensus.
16:54 GTCB GTC Biotherapeutics announces ATryn meets primary endpoint (1.12 -0.06)
Co announces that ATryn has met the statistical requirements for the primary endpoint in the pivotal study for the treatment of patients with hereditary antithrombin deficiency, or HD, undergoing high-risk surgical or childbirth procedures. The primary endpoint was demonstration of non-inferiority to plasma-derived antithrombin in preventing clinically relevant deep vein thromboses, or DVTs, or other thromboembolisms.
16:54 WB Wachovia clarifies exposure to BluePoint Re (35.53 -3.23)
The co announces on Feb. 1, 2008, Moody’s Investors Service announced that it has placed BluePoint Re, a Wachovia Corporation subsidiary, on review for possible downgrade. Wachovia’s 2007 financial results include valuation losses on BluePoint Re assets that resulted in a write-down of substantially all of Wachovia’s $300 mln investment in BluePoint Re. Consequently, Wachovia believes BluePoint Re should have no further negative impact on Wachovia’s financial results.
16:53 SIRF SiRF Technology SIRF guides Q1 EPS to ($0.04)-$0.00 vs $0.24 First Call consensus; sees revs $71-77 mln vs $92.37 mln First Call consensus on earnings call (16.27 +0.22)
16:53 KIM Kimco Realty and Valad announce strategic relationship (36.62 -0.75)
KIM and Valad Property Group (VPG) announce a strategic alliance focused on creating funds management and joint venture opportunities. Pursuant to the alliance, Kimco and Valad intend to work together to develop their respective real estate businesses by leveraging the complimentary distribution networks of both groups. The alliance is expected to focus on the marketing and introduction of funds management products to major pension funds and other institutional investors. As a sign of their commitment to the strategic alliance, Kimco purchased an A$200 mln convertible note issued by a subsidiary of Valad.
16:52 SGTL SigmaTel beats by $0.08, misses on revs; guides Q1 EPS below consensus, revs below consensus (2.94 +1.15)
Reports Q4 (Dec) loss of $0.06 per share, excluding non-recurring items, $0.08 better than the First Call consensus of ($0.14); revenues fell 11.5% year/year to $33.2 mln vs the $35.6 mln consensus. Co issues downside guidance for Q1, sees EPS of ($0.35)-(0.25), excluding non-recurring items, vs. ($0.22) consensus; sees Q1 revs of $17-22 mln vs. $29.14 mln consensus.
16:51 ROCM Rochester Medical misses by $0.02; misses on revs (13.22 +0.13)
Reports Q4 (Dec) earnings of $0.05 per share, $0.02 worse than the First Call consensus of $0.07; revenues rose 64.9% year/year to $8.2 mln vs the $8.7 mln consensus.
16:51 KBR KBR awarded contract to provide engineering, procurement and design interface services for Pazflor FPSO topsides (31.97 -1.43)
16:51 RADN Radyne exploring strategic alternatives; sees FY07 EPS of $0.55-0.59 on revs of $141-144 mln (9.35 +0.70)
Co announces it retained Needham & Company as its financial advisor to assist it in exploring strategic alternatives, including a possible sale of the Company. Needham has previously assisted the Company in evaluating inquiries received from time to time from prospective suitors. Co sees FY07 EPS of $0.55-0.59 vs. $0.64 consensus; see revs of $141-144 mln vs. $145.37 mln consensus.
16:51 NDN 99 Cents Only: Akre Capital amends 13D filing; sends letter to mgmt urging reevaluation (7.79 -0.8
In a filing, Akre Capital discloses 13.4% stake in SC 13D and sends a letter to mgmt urging the co to reevaluate their position on 1) New Store Growth 2) Texas Analysis 3) Excess Cash.
16:50 SLM SLM Corp- Responds to S&P Announcement
Co issued the following statement: We are disappointed by today’s announcement by Standard & Poor’s (S&P). We are committed over the long term to strengthen and improve our investment-grade rating. Notwithstanding a tumultuous 2007, Sallie Mae remains a profitable company, and has been for 35 consecutive years. We are the leading provider of federally guaranteed and private education student loans. We will increase that position in 2008 and in future years. We look forward to working with S&P and the other ratings agencies to demonstrate our financial strength and stability.
16:50 PDLI PDL BioPharma AND EKR Therapeutics sign asset purchase agreement for cardiovascular products (15.36 -0.12)
Cos announce that they have entered into an agreement under which EKR would acquire the rights to PDLI’s cardiovascular products, consisting of Cardene (nicardipine hydrochloride), CardeneSR and new formulations of Cardene in development, as well as Retavase and the development product ularitide. Under the terms of the agreement, PDLI would receive cash payments of $85 mln at closing, up to an additional $85 mln in development and sales milestones for the new Cardene formulations, as well as royalties on sales of the new Cardene formulations and ularitide. PDLI would receive a $25 mln milestone upon the approval of a new formulation of Cardene, which PDLI anticipates will occur well in advance of the November 2009 Cardene I.V. patent expiry. Two additional milestones of $30 million each would be payable upon achievement of $80 million and $150 million of annual net product sales of the new Cardene formulations. EKR also would pay PDLI royalties of 10% and 5% on future net sales of the new Cardene formulations and ularitide, respectively. The transaction has been approved by the boards of directors of both companies and is expected to close during the first quarter of 2008.
16:50 TECHX Equity markets settle lower on weak financials, profit taking
The major averages suffered modest losses across the board today, one day after the stock market concluded it’s best weekly performance in nearly 5 years. Contributing to the weakness were the financials & the retailers as renewed recession talk sparked some selling in the respective recession sensitive spaces. Furthermore, UBS downgraded a handful of credit card companies (AXP, COF, DFS) citing higher than forecast credit losses & resulting lower earnings stemming from a U.S. consumer-led recession. Technically, the major averages posted an ‘Inside day’ as the markets remained mostly range-bound, holding above yesterday’s lows, but failing to breach yesterday’s intraday session highs. Unofficially, the INDU settled @ 12635 -108, SPX @ 1380 -14.50, COMPQ @ 2382 -30.50, NDX @ 1828 -26.50, & RUT @ 723.50 -7.0. Today’s sector strength is seen in Commodities (DBA +2.0%), Energy (OIH +1.8%), Utilities (XLU +1.45%), Coal (KOL +1.2%) while sector weakness is noted in Homebuilders (XHB -6.4%), Regional Banks (RKH -4.0%), Retailers (XRT -3.9%,), & Materials (XLB -1.5%).
16:49 SCUR Secure Computing reports EPS in-line, misses on revs; guides Q1 EPS in-line, revs in-line (9.07 +0.10)
Reports Q4 (Dec) earnings of $0.10 per share, excluding non-recurring items, in-line with the First Call consensus of $0.10; revenues rose 28.1% year/year to $66.5 mln vs the $68.2 mln consensus. Co issues in-line guidance for Q1, sees EPS of $0.07-0.09, excluding non-recurring items, vs. $0.09 consensus; sees Q1 revs of $67-69 mln vs. $66.67 mln consensus. Co says for the first quarter of 2008 billings are expected to be in the range of $76-79 mln.
16:49 SVN Sun-Times Media to consider strategic alternatives (1.38 -0.02)
Co announces that its Board of Directors has begun an evaluation of the co’s strategic alternatives to enhance shareholder value. These alternatives may include, but are not limited to, joint ventures or strategic partnerships with third parties, and/or the sale of the Company or any or all of its assets. The Company also said that, subject to legal requirements, it does not intend to disclose developments arising from the strategic evaluation process unless the Company has entered into a definitive agreement for a transaction that has been approved by its Board of Directors.
16:49 STX Seagate Tech announces 2 cent dividend increase (from $0.10-0.12); $2.5 billion share repurchase program (20.74 -0.19)
The stock is halted.
16:48 SHFL Shuffle Master announces plan to appeal Nevada District Court summary judgment (9.51 -0.71)
Co announces that it plans to appeal the District Court of Nevada’s Friday, Feb 1, 2008 order granting summary judgment to VendingData, now known as Elixir Gaming Technologies, in regard to Shuffle Master’s claims of patent infringement against VendingData’s Poker-1 shuffler. The court has not yet ruled on Shuffle Master’s separate summary judgment motion requesting the return of a $3 million deposit the Company was compelled to make with the court in November 2004 when a preliminary injunction against VendingData’s Poker-1 was granted.
16:48 PKY Parkway Prop beats by $0.10, beats on revs; guides FY08 FFO in-line (36.25 +0.20)
Reports Q4 (Dec) funds from operations of $1.08 per share, $0.10 better than the First Call consensus of $0.98; revenues rose 10.2% year/year to $63.7 mln vs the $61.8 mln consensus. Co issues in-line guidance for FY08, sees FFO of $4.00-4.20 vs. $4.03 consensus.
16:48 CVTX CV Therapeutics and Medlogics Device Corporation sign licensing agreement for CVT’s innovative stent coating technology (8.52 -0.06)
CVTX and Medlogics Device Corporation sign licensing agreement for CVTx’s innovative stent coating technology. CVTX and Medlogics Device announce that the cos have entered into an agreement under which Medlogics has licensed CVTX’s proprietary biopolymer stent coating technology to develop a drug eluting stent. CVTX received Medlogics stock and is entitled to development milestone payments, royalties and other potential payments on future sales of any products incorporating the technology. Medlogics recently received a CE Mark from European regulatory authorities for its Cobalt Super Alloy stent and expects to launch the stent in Europe in the first quarter of 2008. Medlogics expects to utilize CV Therapeutics’ biopolymer stent coating technology to develop a next- generation DES based on the COBRA stent platform.
16:47 NSM National Semi cuts 3Q08 rev outlook (19.02 -0.34)
NSM sees 3Q08 revs of ~$450-455 mln vs $484.68 mln First Call consensus. Co’s revised outlook is attributable mainly to products for wireless handsets and other portable electronic devices. The shortfall in the third quarter is due to lower-than-expected shipments to global original equipment manufacturers (OEMs) as well as handset companies in China which National serves through distribution channels.
16:47 SPRT SupportSoft announces the appointment of Shelly Schaffer as CFO (3.78 +0.14)
Co announces the appointment of Shelly Schaffer as Executive tickerVP and CFO. Ms. Schaffer will join The co at the end of February 2008 as Executive Vice President and will assume the Chief Financial Officer title after SupportSoft files its Annual Report on Form 10-K for 2007 in March.
16:47 RJET Republic Airways reports preliminary passenger traffic results for January 2008 (20.21 -0.42)
Co reports preliminary passenger traffic results for January 2008. The co generated 710.0 mln revenue passenger miles, a 34.1% increase over the same month last year, while available seat miles increased 30.6% to 1.1 bln. Block hours were 63,232 in January 2008, a 24.8% increase over January 2007. Load factor was 65.6% versus 63.9% in January 2007. A total of 1,378,404 passengers were carried during the month, a 36.4% increase over the same month last year.
16:46 CBL CBL & Assoc announces revised annual 2007 FFO guidance (27.43 +0.09)
Co announces that it revises its funds from operations guidance range to $3.09 to $3.11 primarily as a result of the following items: An $18.5 million non-cash write down of marketable real estate securities related to a significant decline in fair value during 4Q07 ($0.16); A decision to delay the previously announced recognition of $7.0 million of fee income from an affiliate of Centro Properties Group due to its uncertainty ($0.04); and approx $0.05 of FFO per share and diluted EPS related to other non-operating items.
16:46 SIGI Selective Insurance beats by $0.04, beats on revs (24.03 +0.2
Reports Q4 (Dec) earnings of $0.60 per share, excluding non-recurring items, $0.04 better than the First Call consensus of $0.56; revenues rose 1.7% year/year to $466.6 mln vs the $458.6 mln consensus. Co issues guidance for FY08, sees EPS of $2.20-2.40, includes $0.05 restructuring charge and $0.18 after-tax catastrophe losses, may not be comparable to $2.21 consensus.
16:46 BBSI Barrett Business announces acquisition of First Employment Services; May be accretive to its earnings by approx. 3-4 cents per diluted share (18.04 -0.16)
The co announces that it has successfully completed its acquisition of First Employment Services. The transaction was previously announced on January 2, 2008, subject to completion of due diligence. First Employment Services, a privately-held staffing company, operates two offices in Arizona, one in Tempe and one in Phoenix. BBSI anticipates that this acquisition may be accretive to its earnings by approximately 3 to 4 cents per diluted share, for the 12-month period following the effective date.
16:44 NWS.A News Corp reports EPS in-line, beats on revs (19.35 -0.06)
Reports Q2 (Dec) earnings of $0.27 per share, in-line with the First Call consensus of $0.27; revenues rose 9.5% year/year to $8.59 bln vs the $8.25 bln consensus.
16:43 PFG Principal Fincl misses by $0.15, reports revs in-line
Reports Q4 (Dec) earnings of $0.86 per share, $0.15 worse than the First Call consensus of $1.01; revenues rose 14.4% year/year to $2.9 bln vs the $2.89 bln consensus.
16:40 LVS Las Vegas Sands misses by $0.15, misses on revs
Reports Q4 (Dec) earnings of $0.20 per share, $0.15 worse than the First Call consensus of $0.35; revenues rose 64.9% year/year to $1.05 bln vs the $1.12 bln consensus.
16:39 SVVS SAVVIS Comm reports Q4 (Dec) results, revs in-line; guides FY08 revs above consensus (21.15 -1.47)
Reports Q4 (Dec) loss of $0.05 per share, includes gains, charges, may not be comparable to the First Call consensus of $0.02; revenues rose 3.9% year/year to $197.8 mln vs the $198.1 mln consensus. Co issues upside guidance for FY08, sees FY08 revs of $910-925 mln vs. $906.26 mln consensus.
16:39 GMXR GMX Resources announces a $100 mln convertible notes offering; intends to use net proceeds to repay existing debt under co’s revolving bank credit facility (28.36 -0.29)
16:38 AXS AXIS Capital beats by $0.29, misses on revs (39.20 -0.80)
Reports Q4 (Dec) earnings of $1.83 per share, excluding non-recurring items, $0.29 better than the First Call consensus of $1.54; revenues fell 0.5% year/year to $805.4 mln vs the $854.7 mln consensus.
16:37 RMBS Rambus misses by $0.04, beats on revs
Reports Q4 (Dec) loss of $0.14 per share, $0.04 worse than the First Call consensus of ($0.10); revenues fell 23.0% year/year to $40.5 mln vs the $40 mln consensus.
16:34 SNCR Synchronoss Tech beats by $0.02, beats on revs
Reports Q4 (Dec) earnings of $0.22 per share, $0.02 better than the First Call consensus of $0.20; revenues rose 79.0% year/year to $36.4 mln vs the $35.7 mln consensus.
16:32 SIRF SiRF Technology reports Q4 (Dec) results, revs in-line
Reports Q4 (Dec) earnings of $0.99 per share, excluding items and may not be comparable to the First Call consensus of $0.32; revenues rose 35.3% year/year to $100.4 mln vs the $101 mln consensus.
16:28 LNC Lincoln National misses by $0.94, misses on revs
Reports Q4 (Dec) earnings of $0.42 per share, $0.94 worse than the First Call consensus of $1.36; revenues fell 0.4% year/year to $2.61 bln vs the $2.76 bln consensus. Lincoln Financial intends to repurchase approximately $500-600 million of stock in 2008, including share repurchase activity that may be supported by proceeds from the previously announced sales of the media properties.
16:25 ILMN Illumina beats by $0.13, beats on revs; guides Q1 EPS above consensus, revs in-line; guides FY08 EPS above consensus, revs above consensus
Reports Q4 (Dec) earnings of $0.38 per share, $0.13 better than the First Call consensus of $0.25; revenues rose 86.4% year/year to $112.6 mln vs the $105.3 mln consensus. Co issues mixed guidance for Q1, sees EPS of $0.33-0.36 vs. $0.26 consensus; sees Q1 revs of $110-115 mln vs. $111.21 mln consensus. Co issues upside guidance for FY08, sees EPS of $1.45-1.60 vs. $1.23 consensus; sees FY08 revs of $500-525 mln vs. $493.82 mln consensus.
16:22 FEIC FEI Company beats on EPS and revs; guides Q1 EPS in-line, revs below consensus (22.10 -1.09)
Reports Q4 (Dec) earnings of $0.25 per share, excluding a $0.15 tax benefit, vs the First Call consensus of $0.26; revenues rose 41.4% year/year to $152.5 mln vs the $150.9 mln consensus. Bookings in the quarter totaled $156.3 million, up 2% compared with $153.3 million in the third quarter of 2007 and down 9% from the record level of $171.7 million for the fourth quarter of 2006. Co issues guidance for Q1, sees EPS of $0.18-0.25, which may not be comparable to $0.30 consensus; sees Q1 revs of $145-152 mln vs. $152.92 mln consensus. Bookings are expected to be above $145 mln.
16:18 BMI Badger Meter beats by $0.02, reports revs in-line
Reports Q4 (Dec) earnings of $0.28 per share, $0.02 better than the First Call consensus of $0.26; revenues rose 8.5% year/year to $57.2 mln vs the $56.6 mln consensus.
16:16 AUDC Audiocodes reports EPS in-line, revs in-line
Reports Q4 (Dec) earnings of $0.08 per share, in-line with the First Call consensus of $0.08; revenues rose 5.9% year/year to $42.8 mln vs the $42.4 mln consensus.
16:12 HAIN Hain Celestial reports EPS in-line, beats on revs; guides FY08 EPS in-line, revs in-line
Reports Q2 (Dec) earnings of $0.43 per share, in-line with the First Call consensus of $0.43; revenues rose 20.0% year/year to $276.2 mln vs the $266 mln consensus. Co issues in-line guidance for FY08, sees EPS of $1.38-1.42 vs. $1.40 consensus; sees FY08 revs of $1.025-1.050 bln vs. $1.03 bln consensus.